symp1

0

H. Allain (France): What is new in the methods to develop new anti-dementia drugs?

M. Bourin (France): Clinical methodology for testing of anxiolytic drugs.

I. Hindmarch (U.K.): The use of psychometric batteries in psychopharmacology.

S. Artigas (Spain): Drug development in major depression.

M. Ackenheil (Germany): Response to treatment as a function of pharmacogenomics.